Report cover image

Acute Myeloid Leukemia Market Growth, Size, Trends Analysis - By Disease, By Treatment, By Route of Administration, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Mar 19, 2025
Length 259 Pages
SKU # SPER20019411

Description

Acute Myeloid Leukemia Market Introduction and Overview

According to SPER Market Research, ‘Global Acute Myeloid Leukemia Market Size – By Disease, By Treatment, By Route of Administration, By End Use – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Acute Myeloid Leukemia Market is predicted to reach 9.73 billion by 2034 with a CAGR of 10.86%.

Acute Myeloid Leukemia (AML) is an aggressive form of blood cancer that originates in the bone marrow and rapidly spreads to the bloodstream, affecting the production of healthy blood cells. The disease is characterized by genetic mutations that cause uncontrolled proliferation of abnormal myeloid cells, leading to anemia, increased infection risk, and uncontrolled bleeding. AML is more common in older adults, but it can affect individuals of all ages.

Restraints: The AML market still confronts many obstacles in spite of its advancements. Access for patients is restricted by the high expense of stem cell transplants and sophisticated therapies, particularly in developing nations. Due to the disease’s extreme heterogeneity, it is challenging to create treatments that work for everyone, which can result in treatment resistance and significant relapse rates.

Scope of the Report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered

By Disease, By Treatment, By Route of Administration, By End Use.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Astellas Pharma Inc., Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY LIMITED, Jazz Pharmaceuticals plc, Merck, Novartis, Otsuka Pharmaceuticals Co. Ltd., Pfizer Inc., Rigel Pharmaceuticals Inc., Sanofi.

Acute Myeloid Leukemia Market Segmentation:

By Disease: Based on the Disease, Global Acute Myeloid Leukemia Market is segmented as; Myeloblastic Leukemia, Myelomonocytic Leukemia, Promyelocytic Leukemia, Monocytic Leukemia and Other Diseases.

By Treatment: Based on the Treatment, Global Acute Myeloid Leukemia Market is segmented as; Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatments.

By Route of Administration: Based on the Route of Administration, Global Acute Myeloid Leukemia Market is segmented as; Parenteral and Oral.

By End Use: Based on the End Use, Global Acute Myeloid Leukemia Market is segmented as; Hospitals and Clinics, Specialty Centers, Homecare Setting and Ambulatory Care Centers.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

259 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Acute Myeloid Leukemia Market Manufacturing Base Distribution, Sales Area, Interface Type
6.2. Mergers & Acquisitions, Partnerships, Interface Launch, and Collaboration in Global Acute Myeloid Leukemia Market
7. Global Acute Myeloid Leukemia Market, By Disease 2021-2034 (USD Million)
7.1. Myeloblastic Leukemia
7.2. Myelomonocytic Leukemia
7.3. Promyelocytic Leukemia
7.4. Monocytic Leukemia
7.5. Other Diseases
8. Global Acute Myeloid Leukemia Market, By Treatment 2021-2034 (USD Million)
8.1. Chemotherapy
8.2. Targeted Therapy
8.3. Immunotherapy
8.4. Other Treatments
9. Global Acute Myeloid Leukemia Market, By Route of Administration 2021-2034 (USD Million)
9.1. Parenteral
9.2. Oral
10. Global Acute Myeloid Leukemia Market, By End Use 2021-2034 (USD Million)
10.1. Hospitals and Clinics
10.2. Specialty Centers
10.3. Homecare Setting
10.4. Ambulatory Care Centers
11. Global Acute Myeloid Leukemia Market Forecast, 2021-2034 (USD Million)
11.1. Global Acute Myeloid Leukemia Market Size and Market Share
12. Global Acute Myeloid Leukemia Market, By Region, 2021-2034 (USD Million)
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. Astellas Pharma Inc.
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Interface summary
13.1.4. Recent developments
13.2. Bristol-Myers Squibb Company
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Interface summary
13.2.4. Recent developments
13.3. DAIICHI SANKYO COMPANY LIMITED
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Interface summary
13.3.4. Recent developments
13.4. Jazz Pharmaceuticals Plc
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Interface summary
13.4.4. Recent developments
13.5. Merck
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Interface summary
13.5.4. Recent developments
13.6. Novartis
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Interface summary
13.6.4. Recent developments
13.7. Otsuka Pharmaceuticals Co. Ltd.
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Interface summary
13.7.4. Recent developments
13.8. Pfizer Inc.
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Interface summary
13.8.4. Recent developments
13.9. Rigel Pharmaceuticals Inc.
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Interface summary
13.9.4. Recent developments
13.10. Sanofi
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Interface summary
13.10.4. Recent developments
14. Conclusion
15. List of Abbreviations
16. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us